Nicotinamide Mononucleotide Restores Pancreatic β-Cell Function in Type 2 Diabetes through SIRT6-HIF-1α-Mediated Mitochondrial Stress Adaptation and Glycolytic Reprogramming

Technical Summary: Nicotinamide Mononucleotide Restores Pancreatic β-Cell Function in Type 2 Diabetes through SIRT6-HIF-1α-Mediated Mitochondrial Stress Adaptation and Glycolytic Reprogramming

Problem Statement
Type 2 diabetes mellitus (T2DM) is characterized by progressive pancreatic β-cell dysfunction and loss of mass, driven by a confluence of stressors including oxidative stress, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction. While mitochondrial impairment is recognized as a central pathogenic event leading to reduced ATP production, increased reactive oxygen species (ROS), and defective glucose-stimulated insulin secretion (GSIS), effective strategies to restore mitochondrial resilience and preserve β-cell function remain limited. Although Nicotinamide Mononucleotide (NMN), a precursor of NAD⁺, has shown potential in improving mitochondrial homeostasis, the specific molecular mechanisms by which it regulates mitochondrial adaptation and protects β-cells under diabetic conditions are not fully understood.

Methodology
The study employed a multi-faceted approach combining in vitro cellular models and in vivo animal models to investigate the protective effects of NMN:

• In Vitro Models: Rat pancreatic islet cell tumor (INS1) cells were exposed to high glucose (HG, 60 mmol/L) to simulate diabetic stress. Cells were treated with NMN and compared against controls and other metabolic compounds (Vitamin C, CoQ9, GLP-1, Metformin).
• In Vivo Models: Eight-week-old db/db male mice (a model of T2DM) and C57BL/6J wild-type mice were administered NMN (200 mg/kg) or double-distilled water for 8 weeks.
• Assays and Analyses:
  • Cell Viability and Metabolism: CCK-8 assays measured cell survival; lactate production and glycolytic enzyme expression were assessed to evaluate metabolic reprogramming.
  • Mitochondrial Function: Mitochondrial ROS levels, membrane potential (TMRM staining), and ATP production were quantified. Mitochondrial morphology was visualized via immunofluorescence (TOM20).
  • Molecular Mechanisms: The study utilized siRNA-mediated knockdown of HIF-1α and SIRT6 to determine their necessity in NMN's effects. Immunohistochemistry and immunofluorescence were used to analyze protein expression levels of SIRT6, HIF-1α, glycolytic enzymes (PKM2, GAPDH, LDHA), and mitochondrial stress markers (HSP60, GRP78).
  • Physiological Metrics: In mice, body weight, fasting blood glucose, serum insulin, and pancreatic islet morphology (insulin immunoreactivity) were monitored.

Key Contributions and Results

1. NMN Protects β-Cells from Hyperglycemic Stress:
   NMN demonstrated the strongest protective effect against HG-induced injury among tested compounds. It significantly reversed mitochondrial defects caused by high glucose, including the reduction of mitochondrial ROS accumulation, restoration of mitochondrial membrane potential, and recovery of ATP production.

2. Induction of Mitochondrial Stress Adaptation and Glycolytic Reprogramming:
   High glucose alone failed to sufficiently activate mitochondrial adaptive responses. NMN treatment selectively upregulated mitochondrial stress-response markers (specifically HSP60) without affecting ER stress markers (GRP78). Concurrently, NMN promoted a metabolic shift characterized by:

   • Increased expression of glycolytic regulators (HIF-1α, PKM2, GAPDH, LDHA).
   • Reduced expression of PDHA1 (a link to the TCA cycle).
   • Enhanced lactate production, indicating a shift toward glycolytic ATP generation to sustain energy under stress.

3. Essential Role of HIF-1α:
   Genetic silencing of HIF-1α abolished the beneficial effects of NMN. In the absence of HIF-1α, NMN failed to reduce mitochondrial ROS, restore ATP levels, induce mitochondrial adaptive responses, or upregulate glycolytic enzymes. This confirms HIF-1α is an essential mediator for NMN-induced metabolic adaptation.

4. SIRT6 as the Upstream Regulator:
   The study identified SIRT6 as the critical NAD⁺-dependent regulator linking NMN to HIF-1α activation. SIRT6 expression was diminished in diabetic conditions but restored by NMN. Knockdown of SIRT6 prevented the NMN-mediated restoration of HIF-1α and downstream glycolytic enzymes, establishing the SIRT6-HIF-1α axis as the primary signaling pathway.

5. In Vivo Efficacy:
   Long-term NMN administration in db/db mice resulted in:

   • Reduced body weight gain and improved fasting blood glucose.
   • Increased circulating insulin levels.
   • Preservation of pancreatic islet architecture and enhanced insulin immunoreactivity.
   • Restoration of SIRT6 expression and HIF-1α-dependent glycolytic responses in pancreatic tissues.

Significance and Claims
The paper claims to identify a previously unrecognized mechanism by which NMN preserves β-cell function in T2DM. Specifically, it posits that NMN activates a SIRT6-HIF-1α-mediated mitochondrial adaptive pathway. Rather than merely suppressing oxidative stress, NMN facilitates a compensatory metabolic reprogramming where β-cells enhance glycolytic flux to maintain ATP production during mitochondrial stress.

The authors conclude that this SIRT6-HIF-1α axis represents a critical signaling pathway for β-cell stress resistance. By enhancing mitochondrial adaptive capacity and promoting metabolic flexibility, NMN offers a novel mechanistic insight into NAD⁺ metabolism-based strategies for preventing β-cell failure in T2DM. The study suggests that targeting this pathway could provide new therapeutic avenues to delay the progression of β-cell decline, although the authors note that further validation in human islets and deeper investigation into the specific nature of SIRT6-HIF-1α interaction (e.g., direct regulation of stability vs. transcription) are required.